Showing 2361-2370 of 3315 results for "".
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging-2/2476749/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a Medscape
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging/2476720/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a
- One Week Left to Submit Nominations for OWL Awardshttps://modernod.com/news/one-week-left-to-submit-nominations-for-owl-awards/2476721/OWL is accepting nominations for the
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Novel Approaches to Cataract Surgery are Challenging Phaco; Cost May Determine Their Successhttps://modernod.com/news/novel-approaches-to-cataract-surgery-are-challenging-phaco-cost-may-determine-their-success/2476591/Ultrasonic phacoemulsification (USP) has been the dominant method of cataract surgery globally over the past half century, but novel alternative approaches are attempting to improve or replace it, according to a Market Scope report. These include robotic cataract machines, ultrasonic-less
- Johnson & Johnson Vision Showcases the Rising Burden of Myopia, New Contact Lens and Surgical Technologies at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-the-rising-burden-of-myopia-new-contact-lens-and-surgical-technologies-at-arvo/2476549/Johnson & Johnson Vision showcased new research abstracts covering topics across a range of eye health needs at the Association for Research in Vision and Ophthalmology annual meeting (ARVO) in Vancouver, Canada, April 28-May 2, 2019. Presentations included the first predictive model for dire
- Novaliq and BLP Management Group Establish New Company, Betaliq, to Leverage EyeSol Technology to Treat Glaucomahttps://modernod.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/Novaliq and BLP Management group announced the formation and funding of Betaliq. The Tampa-based company’s pipeline consists of two preservative-free glaucoma drug candidates based on new in class and best in class ß-blocker molecules using Novaliq’s waterfree EyeSol technology. Two EyeSol-
- Lightmed and Mexico’s Leading Pediatric Hospitals Partner in Childhood Blindness Preventionhttps://modernod.com/news/lightmed-and-mexicos-leading-pediatric-hospitals-partner-in-childhood-blindness-prevention/2476428/Lightmed Corp. announced the successful installation and support of 34 LIGHTLas 810 photocoagulator lasers across 32 Mexican states. Mexico’s Ministry of Health initially purchased 18 Lightmed lasers to be placed in areas with the most urgent need. Soon after, they ordered an additional 16 units
- FDA Prepares for Possible Device Shortages After Gas Leaks Lead to Closure of Sterilization Planthttps://modernod.com/news/fda-prepares-for-possible-device-shortages-after-gas-leaks-lead-to-closure-of-sterilization-plant/2479583/The FDA is working to prevent potential shortages of medical devices after the closure of an Illinois sterilization plant, which was due to a state environmental protection order, according to a